Welcome to our dedicated page for Xenetic Biosciences SEC filings (Ticker: XBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xenetic Biosciences, Inc. (NASDAQ: XBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. According to these filings, Xenetic is a Nevada-incorporated biopharmaceutical company whose common stock trades on The Nasdaq Stock Market under the symbol XBIO, and it focuses on a DNase-based immuno-oncology platform targeting neutrophil extracellular traps (NETs) in difficult to treat cancers.
Through Xenetic’s Form 8-K current reports, investors can review announcements of material events, such as quarterly financial results and the entry into an underwriting agreement for an underwritten public offering of common stock under an effective shelf registration statement on Form S-3. These filings describe, among other things, the number of shares offered, the public offering price, estimated net proceeds and intended uses of proceeds, including working capital, general corporate purposes and advancement of the DNase technology.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to stockholders at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm and an advisory vote on named executive officer compensation. The proxy materials also explain record dates, virtual meeting procedures and how stockholders of record and beneficial owners may vote.
On Stock Titan, these and other SEC documents are updated in near real time from EDGAR. Users can review Xenetic’s 8-Ks for financial result announcements, shelf registration usage and other corporate developments, as well as proxy statements for governance and compensation information. The platform’s AI-powered summaries help interpret complex sections of filings, highlight key terms in offerings and corporate actions, and make it easier to locate information about topics such as capital raises, collaboration agreements and the company’s DNase-based oncology focus without reading every page in full.
Xenetic Biosciences, Inc. filed an amendment to its annual report to add the Part III sections on directors, executive compensation, ownership and related-party transactions, and to update the cover-page share count to 2,291,056 common shares as of April 17, 2026. The filing details the board’s committee structure and independence, insider trading and related-party policies, and a single named executive officer, Interim CEO and CFO James Parslow. His 2025 total compensation was $536,027, including a $100,000 retention bonus and benefits, and he holds multiple option grants with exercise prices ranging from $3.88 to $548.40 per share. Pay-versus-performance tables show Compensation Actually Paid to the CEO moving broadly in line with total shareholder return and net losses, including a 2025 net loss of $2,680,860 and a total shareholder return value of $76.11 on a hypothetical $100 investment. The amendment also discloses 2025 audit and audit-related fees of $208,000, equity plan overhang of 115,622 options outstanding with 137,985 shares remaining available for issuance, and principal stockholders such as Renaissance Technologies LLC with 178,509 shares, or 7.8% of the common stock.
Xenetic Biosciences approved a new equity award for its Interim Chief Executive Officer and Chief Financial Officer, James Parslow, under its Amended and Restated Equity Incentive Plan. The grant consists of 100,000 shares of restricted stock, documented in a restricted stock award agreement dated April 21, 2026.
Of these shares, 7,000 vest immediately on the grant date. The remaining 93,000 shares will vest in three equal installments on each of the first, second, and third anniversaries of April 21, 2026. This structure is designed to tie Mr. Parslow’s compensation to ongoing service over several years.
PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.
Xenetic Biosciences, Inc. reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock as a restricted stock grant. The award was made at a stated price of $0.00 per share, indicating compensation rather than a market purchase.
According to the vesting terms, 7,000 shares vest on the grant date, and one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026. Following this grant, Parslow directly holds 100,000 shares of Xenetic Biosciences common stock.
Xenetic Biosciences reported a full-year 2025 net loss of approximately $2.7 million, as it continued investing in its DNase-based immuno-oncology programs targeting difficult-to-treat cancers. Royalty revenue from its sublicense with Takeda grew about 19% to $3.0 million, up from $2.5 million in 2024.
Research and development expenses were $3.1 million, down from $3.3 million, partly because a $0.7 million impairment recorded in 2024 did not recur, while DNase process development spending increased. General and administrative costs fell about 20% to $2.7 million. Xenetic ended 2025 with roughly $7.9 million in cash, about $1.7 million higher than the prior year, primarily from net proceeds of around $4.0 million raised in an October 2025 underwritten public offering.
Xenetic Biosciences is an early-stage immuno-oncology company focused on DNase technology to improve treatment of difficult solid tumors, initially pancreatic and colorectal cancers. The approach targets neutrophil extracellular traps that contribute to tumor growth and resistance to chemotherapy, radiotherapy and immunotherapy.
The company is advancing a systemic DNase I program toward first-in-human studies and exploring DNase‑armored CAR T cells to improve cell therapy performance in solid tumors. Development is executed largely through external partners and academic collaborations, including Scripps Research, the University of Virginia, Catalent and PeriNess.
Xenetic has begun a formal strategic review, considering options such as a sale, asset sale or reverse merger, with outcomes that could significantly alter ownership. The business remains unprofitable, expects substantial additional funding needs, and currently generates modest royalties from a PolyXen out‑license to Takeda while prioritizing DNase over legacy platforms.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed a Schedule 13G reporting beneficial ownership of 178,509 shares of Xenetic Biosciences, Inc. common stock, representing 7.79% of the outstanding class.
They report sole voting and dispositive power over all 178,509 shares, with no shared power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Xenetic Biosciences.
Xenetic Biosciences, Inc. reported that its 2025 Annual Meeting of Stockholders, originally adjourned from December 11, 2025 to January 8, 2026 to seek more proxies and achieve a quorum, was again adjourned on January 8, 2026 without any business being conducted because a sufficient number of shares was not represented.
The company plans to reconvene the Annual Meeting at a future date and time that has not yet been set and will give stockholders the required advance notice before the new meeting.
Xenetic Biosciences, Inc. filed an 8-K announcing it furnished a press release with results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference into Item 2.02.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes customary forward-looking statements language outlining risk factors and cautions.
Xenetic Biosciences (XBIO) filed its Q3 2025 10‑Q, reporting royalty-driven revenue of $1,026,957 and a net loss of $509,940 (basic and diluted loss per share $0.33). Royalties stem from a sublicense with Takeda and rose versus last year.
Operating expenses included R&D $756,482 and G&A $815,209. Cash was $4,121,599 and total current liabilities were $1,111,775 as of September 30, 2025, reflecting continued focus on DNase research. Management believes existing resources fund operations for at least twelve months from issuance.
After quarter-end, the company completed an underwritten offering of 735,000 common shares at $6.12 per share, with estimated net proceeds of ~$3.9 million. Xenetic and its board began a strategic review considering alternatives, including a potential business combination or sale; the process has no set timetable and outcomes are uncertain. Common shares outstanding were 2,291,056 as of November 7, 2025.